Clinical trials: Aldosterone Disorder
Metabolic Syndrome X
Diurnal Variation of Plasminogen Activator Inhibitor-1
To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning administration.
- Trial name
- NCT00515021
- Testing
- Eplerenone (Morning), Eplerenone (Night-time)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Vanderbilt University Medical Center
COVID-19, SARS-CoV-2 Infection
Novel Experimental COVID-19 Therapies Affecting Host Response
The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing…
- Conditions
- COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
- Trial name
- NECTAR (NCT04924660)
- Testing
- TXA127, TRV027, Fostamatinib
- Where
- 51 sites in United States
- Volunteers
- 1,060 people
- Sponsor
- Sean Collins